Home LiteratureArticle Details
PMID: 19734041 Published · ppublish English Evaluation Study Journal Article

Tumour control by whole brain irradiation of anti-VEGF-treated mice bearing intracerebral glioma.

European journal of cancer (Oxford, England : 1990) ·Vol. 45 ·No. 17 ·2009-11-00 ·Pages 3074-80

Verhoeff JJ, Stalpers LJ, Claes A, Hovinga KE, Musters GD, Peter Vandertop W, Richel DJ, Leenders WP, van Furth WR

Abstract

Tumour angiogenesis and invasion are key features of glioblastoma multiforme (GBM). Angiogenesis inhibitors increase progression-free survival (PFS) of recurrent GBM patients. VEGF inhibition controls the bulk tumour growth by inhibition of angiogenesis, but does not inhibit the invasive tumour component. We investigated if invasive tumour growth can be controlled by combining anti-VEGF treatment with irradiation of tumour plus surrounding brain in an orthotopic murine model for GBM. GBM cell line U251-NG2 was inoculated through a guide screw in the right frontal lobe of 53 athymic nude mice. Pegaptanib (a slow-releasing aptamer against VEGF) was injected in the tumour bed either or not followed by irradiation treatment with implanted I-125 seeds. Pegaptanib and/or irradiation were compared with sham-treated controls, resulting in four groups of 10-15 mice each. After 6 weeks of treatment, histological analysis was performed on all brains. VEGF inhibition by locally deposited pegaptanib decreased tumour blood vessel density, and increased tumour hypoxia. Pegaptanib treatment still allowed the formation of tumour satellites. Irradiation decreased tumour size and suppressed formation of satellites. Combined pegaptanib plus irradiation further increased PFS. Tumour size directly correlated with PFS. The anti-tumour effects of local VEGF inhibition are partially circumvented by the formation of invasive tumour satellites. Additional irradiation is effective in slowing down proliferation of these invasive tumour components.

MeSH Terms
Angiogenesis Inhibitors/therapeutic use Animals Aptamers, Nucleotide/therapeutic use Brain Neoplasms/blood supply,drug therapy,pathology,radiotherapy Combined Modality Therapy Disease Models, Animal Disease-Free Survival Female Glioblastoma/blood supply,drug therapy,pathology,radiotherapy Humans Mice Mice, Nude Neoplasm Invasiveness Neoplasm Transplantation Neovascularization, Pathologic/prevention & control Treatment Outcome Vascular Endothelial Growth Factor A/antagonists & inhibitors
Chemicals
Angiogenesis Inhibitors Aptamers, Nucleotide Vascular Endothelial Growth Factor A pegaptanib
Authors & Affiliations
9 authors, click to expand affiliations / ORCID
Verhoeff Joost J C
Department of Radiation Oncology, Academic Medical Center, Amsterdam, The Netherlands. j.j.verhoeff@amc.nl
Stalpers Lukas J A
Claes An
Hovinga Koos E
Musters Gijsbert D
Peter Vandertop W
Richel Dick J
Leenders William P J
van Furth Wouter R
Article Info
Journal
European journal of cancer (Oxford, England : 1990)
Abbr.
Eur J Cancer
ISSN
1879-0852
Published
2009-11-00
Epub
2009-00-04
Pages
3074-80
Language
English
Region
England
NLM ID
9005373
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com